Dividends & Buybacks ·
TELA Bio, Inc. received notification from Nasdaq on September 15, 2026, that its common stock is subject to delisting…
TELATELA Bio, Inc.
TELA Bio, Inc. received notification from Nasdaq on September 15, 2026, that its common stock is subject to delisting because the minimum bid price remained below $1.00 for 30 consecutive business days and the company failed to regain compliance within the 180-day grace period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the outcome. To address the deficiency, TELA Bio filed a proxy statement on September 14, 2026, seeking shareholder approval for a reverse stock split with a ratio ranging from 1-for-5 to 1-for-15 at a special meeting scheduled for October 8, 2026. The company operates in the medical device industry, specializing in wound care and tissue regeneration technologies.